AA
PLRX icon

ALPS Advisors’s Pliant Therapeutics PLRX Stock Holding History

ALPS Advisors’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-45,261
Closed -$61.1K – 1053
2025
Q1 		$61.1K Sell
45,261
-3,949
-8% -$24K ﹤0.01% 986
2024
Q4 		$648K Buy
49,210
+972
+2% +$13.3K ﹤0.01% 567
2024
Q3 		$541K Buy
48,238
+1,164
+2% +$14.6K ﹤0.01% 596
2024
Q2 		$506K Buy
47,074
+4,589
+11% +$59.2K ﹤0.01% 574
2024
Q1 		$633K Buy
42,485
+1,423
+3% +$23.5K ﹤0.01% 565
2023
Q4 		$744K Sell
41,062
-3,117
-7% -$47.4K 0.01% 546
2023
Q3 		$766K Buy
44,179
+696
+2% +$12.1K 0.01% 531
2023
Q2 		$788K Buy
43,483
+11,361
+35% +$269K 0.01% 536
2023
Q1 		$854K Sell
32,122
-951
-3% -$27.1K 0.01% 502
2022
Q4 		$639K Buy
+33,073
New +$691K 0.01% 546

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

ALPS Advisors's PLRX Position: Q2 2025 in Review

ALPS Advisors sold out of Pliant Therapeutics (PLRX) in Q2 2025, closing a stake of 45,261 shares — an estimated $61.1K sold.

ALPS Advisors first reported a position in PLRX in Q4 2022 and held it in 10 quarters. The position peaked at $854K in Q1 2023. 114 funds tracked by Wall St. Rank hold PLRX as of Q2 2025.

  • ALPS Advisors reported no remaining Pliant Therapeutics position as of Q2 2025 after selling out during the quarter.
  • ALPS Advisors sold 45,261 Pliant Therapeutics shares in Q2 2025, an estimated $61.1K.
  • ALPS Advisors first reported a position in Pliant Therapeutics in Q4 2022 and held it in 10 quarters.
  • ALPS Advisors's Pliant Therapeutics position peaked at $854K in Q1 2023.
  • 114 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2025.

Based on ALPS Advisors's 13F filing for Q2 2025, filed 11 Aug 2025.